These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39279310)

  • 21. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRRT genomic signature in blood for prediction of
    Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?
    Sowa-Staszczak A; Pach D; Stefańska A; Tomaszuk M; Lenda-Tracz W; Mikołajczak R; Pawlak D; Chrzan R; Gilis-Januszewska A; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
    Nucl Med Rev Cent East Eur; 2011; 14(2):73-8. PubMed ID: 22219146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing precision: A predictive model for
    Akhavanallaf A; Joshi S; Mohan A; Worden FP; Krauss JC; Zaidi H; Frey K; Suresh K; Dewaraja YK; Wong KK
    Theranostics; 2024; 14(9):3708-3718. PubMed ID: 38948061
    [No Abstract]   [Full Text] [Related]  

  • 27. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
    Marinova M; Mücke M; Mahlberg L; Essler M; Cuhls H; Radbruch L; Conrad R; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):38-46. PubMed ID: 28864881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors.
    Adnan A; Kudachi S; Ramesh S; Prabhash K; Basu S
    Nucl Med Commun; 2019 Sep; 40(9):947-957. PubMed ID: 31343606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.
    Gujarathi R; Abou Azar S; Tobias J; Polite BN; Setia N; Feinberg N; Appelbaum DE; Keutgen XM; Liao CY
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39093924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
    Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
    Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
    Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
    Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival predictors of
    Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
    Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
    Campana D; Capurso G; Partelli S; Nori F; Panzuto F; Tamburrino D; Cacciari G; Delle Fave G; Falconi M; Tomassetti P
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1197-205. PubMed ID: 23619938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort.
    Heckert JM; Kipnis ST; Kumar S; Botterbusch S; Alderson A; Bennett B; Creamer C; Eads JR; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Katona BW
    Oncologist; 2020 Jul; 25(7):572-578. PubMed ID: 32141667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.